Objectives: To provide a comprehensive description of consumptive hypothyroidism syndrome (CHS), a severe form of hypothyroidism that occurs due to the high expression levels of thyroid hormone inactivation enzyme type 3 deiodinase (D3) in tumors. Study Design: Case report and systematic review. Results: A 7-month-old girl with a diagnosis of massive hepatic hemangioendotheliomas was treated with high doses of thyroid hormones and tumor-directed chemotherapy with vincristine. The tumor displayed excellent response, and euthyroid status was regained. A systematic review on the databases PubMed/Medline and Embase was performed, using the term "Consumptive AND "Hypothyroidism." From the 33 selected references, we extracted 42 case reports of CHS: 36 children and 6 adults. The laboratory profile at diagnosis displayed high TSH and low T 4 and T 3 serum levels. The serum reverse T 3 and D3 activity levels were high in all patients tested. In children, 97% had vascular tumors, whereas in adults 33% were vascular tumors, 33% fibrous tumors, and 33% gastrointestinal stromal tumors. The conservative treatment was predominant in children, while in adults all cases were treated with surgery. Death occurred in 16% of children and 33% of adults. Conclusions: CHS is a rare form of hypothyroidism that occurs in children and adults, usually linked to hepatic vascular tumors. The condition is associated with high lethality. Prompt diagnosis, followed by high-dose thyroid hormone replacement and tumor-directed therapy are the keys to optimize outcomes.
Introduction
Thyroid hormones play an essential role in regulating metabolic functions in humans. The fine-tuning of thyroid hormone metabolism at tissue level is made by the widely expressed iodothyronine deiodinase enzymes, which activate and inactivate thyroid hormones. Whereas type 1 and type 2 deiodinase (D1 and D2) convert thyroxine (T 4 ) into the active hormone triiodothyronine (T 3 ), type 3 deiodinase (D3) turns T 4 and T 3 into its inac- tive products reverse T 3 (rT 3 ) and diiodothyronine (T 2 ), respectively [1] .
Consumptive hypothyroidism syndrome (CHS) is an uncommon and severe form of hypothyroidism that occurs due to high levels of D3 expression by neoplastic tissues, resulting in high rates of thyroid hormone inactivation. It was first described by Huang et al. [2] , with several other CHS cases reported thereafter. Although CHS has been initially noted in neonates and children with vascular tumors, it is not restricted to this age group or type of tumor. The CHS clinical course is variable, as well as the treatment modalities and the therapeutic strategies employed. Briefly, treatment has 2 aims: (1) to restore thyroid hormone levels, which is achieved with the administration of high doses of levothyroxine (LT 4 ) in association or not with liothyronine (LT 3 ), and (2) direct treatment of the tumor that expresses high D3 activity [3] . Due to the rarity of the syndrome, the treatment strategies described are quite variable.
In this study, we report a case of CHS cured after treatment of the tumor with chemotherapy. We also made a systematic literature review, with a summarized description of the clinical characteristics, treatments, and outcomes of this rare syndrome.
Case Report
A 7-month-old female patient was referred to our institution (Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil), with a diagnosis of massive hepatic hemangioendotheliomas, extensive pneumonia in the right lung, heart failure, cholestasis, and clinical hypothyroidism. Her 33-year-old mother had 2 previous pregnancies and attended scheduled prenatal consultations. The patient was delivered by a cesarean section at 32 weeks of gestation due to preeclampsia. Her birth weight was 1,830 g, with an Apgar score of 7 and 9 at the first and fifth minute, respectively. After birth, the baby presented bacterial meningitis and sepsis, with prolonged neonatal intensive care unit (NICU) hospitalization. During the NICU stay, she had a diagnosis of hypothyroidism, which required high doses of LT 4 (up to 500 μg per day) to normalize serum TSH levels. The patient developed liver failure and was then transferred to our institution, a reference center for liver transplantation. At admission to our hospital, her weight was 4,500 g. The physical examination showed a distended abdomen, with collateral circulation, jaundice, and hepatomegaly. Due to continued ventilatory support during the NICU stay, a tracheostomy was performed, and she was being fed by tube feeding. The initial laboratory evaluation showed elevated liver enzymes, aspartate aminotransferase of 4. , respectively), and low total T 3 levels (0.29 nmol/L, RV 1.23-3.08). Based on these results, the LT 4 dose was increased to 500 μg/day (this being the highest dose) and LT 3 to 40 μg/day to achieve a euthyroid state during hospitalization. Thyroid ultrasound displayed a topical and homogeneous gland, with regular contours and increased age-related size (total volume of 2.4 mL, RV 0.2-2.7). Thyroid scintigraphy also showed a functional and topical gland. Based on clinical and laboratory contexts, and reaffirmed by an elevated rT 3 serum level of 2.72 nmol/L (RV 0.17-0.35), a diagnosis of consumptive hypothyroidism secondary to hepatic hemangioendotheliomas was established.
Hepatic hemangioendotheliomas treatment with vincristine was instituted. The patient received infusions of vincristine once a week, for 6 weeks, that resulted in involution of the tumor. She was discharged after 1 month of hospitalization, weighing 5,600 g, with a resolution of jaundice; she had no ventilatory support and was eating orally with no tube feeding. Thyroid function tests (under LT 4 replacement) were as follows: TSH of 5.32 mIU/mL, total T 4 of 171.2 nmol/L, free T 4 of 28.4 nmol/L, and total T 3 of 0.97 nmol/L. The patient had an excellent response to therapy, with a full resolution of the hepatic hemangioendotheliomas. She is now a healthy 9-year-old child, and no longer requires LT 4 treatment.
The parents of the patient provided written informed consent to this case report, and the reporting was approved by our institutional Ethics Committee.
Systematic Review
A search on the databases PubMed/Medline and Embase, using the term "Consumptive AND Hypothyroidism", with no language filters, on April 6, 2017, retrieved 31 and 39 results, respectively. Based on title and abstract content, we selected 25 case reports of CHS. We also searched the references of all selected articles and identified 7 additional case reports and 1 meeting abstract of interest. Finally, from the 33 selected references, we extracted 41 case reports of CHS. After the inclusion of the present case, a total of 42 cases (36 children and 6 adults) were included in the literature review. A summarized description of the clinical characteristics, treatments, and outcomes of this rare syndrome is provided.
The planning and reporting of this systematic review was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines [4] .
Consumptive Hypothyroidism in Children
The clinical characteristics of CSH in children are depicted in Table 1 . In this group of patients, 56% (17/30) were female (missing data of age in 6 cases), with a median age at diagnosis of 1.6 months (P25-P75: 1.0-2.9). The laboratory profile displayed high TSH levels at diagnosis (median of 62 mIU/L, P25-P75: 22-134) and low T 4 and T 3 serum levels. The serum rT 3 levels were high in all patients tested. Interestingly, 32% (7/22) In the group of CHS children, 97% (35/36) had vascular tumors, with hepatic vascular tumors representing 88% (32/36) of cases, parotid hemangiomas 5% (2/36), cutaneous hemangiomatosis 2% (1/36), and fibrosarcoma 2% (1/36). Of the hepatic tumors, 15 were hemangiomas, 10 were hemangioendotheliomas, 1 was hepatic hemangioma/hemangioendothelioma, and 5 were diffuse infantile hemangiomas. Because there is a high risk of bleeding associated with vascular tumor biopsy, only 3 patients underwent tissue sampling. High D3 activity was confirmed in all tumor specimens.
We observed considerable variation in tumor treatment strategies, with medical treatment being the predominant one. Medications used for tumor-directed therapy consisted of corticosteroids, propranolol, interferon, vincristine, Cytoxan, and cyclophosphamide (Table 2) .
Surgical treatment was performed in 25% (8/32) of cases. Three patients had missing information about tumor treatment, and 1 patient died before transplantation and received no medications but LT 4 replacement. The modalities of surgical treatment consisted of 2 liver transplantations, 2 resections (hepatic hemangioma and fibrosarcoma), 2 embolizations (hepatic hemangioma and hepatic hemangioendothelioma), and 2 hepatic artery ligations. Radiotherapy was employed in 1 case of hepatic hemangioma. Two patients had spontaneous tumor resolution (hepatic hemangioma and cutaneous hemangiomatosis). The frequency of the different tumor-directed treatment modalities employed in children with CHS is summarized in Figure 1 .
The treatment of hypothyroidism consisted of LT 4 administration in 94% (32/34) of patients, with 38% (13/34) requiring it in association with LT 3 . In 1 case only LT 3 was used. There were missing data about hormone replacement of 2 patients. The median maximum dose of LT 4 was 69 μg/day (P25-P75: 42-122) and of LT 3 30 μg/day (P25-P75: 11-84). Sixteen percent (6/36) of patients died: 4 cases of hemangioendotheliomas, 1 case of hemangioma, and 1 case of hemangioma/hemangioendothelioma.
Consumptive Hypothyroidism in Adults
Adult patients comprise 14% (6/42) of all reported CHS cases. The clinical characteristics of the group of adults with CSH are depicted in Table 1 . In this group of patients, 50% (3/6) were female, with a median age of 50 years (P25-P75: 41-58). As in the children's group, the laboratory profile showed high TSH levels at diagnosis (median of 64 mIU/L, P25-P75: 26-82), low T 4 and T 3 , and elevated levels of rT 3 .
Of note, tumor histology in the adult population differed somewhat from pediatric patients. Hepatic vascular tumors represented only 33% (2/6) of cases (1 hemangioma and 1 hemangioendothelioma). Gastrointestinal stromal tumors (GIST) and fibrous tumors C, corticosteroid; Inf, interferon; Eb, embolization; HAL, hepatic artery ligation; Tx, transplantation; Rdt, radiotherapy; Rsc, resection; V, vincristine; Cyt, Cytoxan; Pro, propranolol; Clf, cyclophosphamide; SR, spontaneous resolution; Imt, imatinib; Srf, sorafenib; Snt, sunitinib; LT 4 , levothyroxine; LT 3 , liothyronine; HmH, hepatic hemangioma; HeH, hepatic hemangioendothelioma; IDHmH, infantile diffuse hepatic hemangioma; GIST, gastrointestinal stromal tumor; FT, fibrous tumor; PHmH, parotid hemangioma; CH, cutaneous hemangiomatosis, FS, fibrosarcoma; M, male; F, female; MD, missing data.
a Treatment data not available for 2 children. b No specific tumor-directed treatment described.
Eur Thyroid J 2017;6:321-327 DOI: 10.1159/000481253 accounted for 33% (2/6) of cases each. All adult patients underwent liver biopsy, and functional assays confirmed high D3 activity levels.
All adult patients underwent tumor surgery: 1 partial hepatectomy and 1 transplantation in the vascular tumors, 1 partial gastrectomy and transverse colectomy en bloc resection and 1 laparoscopic abdominal resection for the GISTs. The type of resection for the fibrous tumors is not specified. Hypothyroidism treatment was comprised of LT 4 administration in 83% (5/6) of patients, and only 1 (16%) patient received LT 3 in association with LT 4 . The median maximum dose of LT 4 was 300 μg/day (P25-P75: 150-300). Thirty-three percent (2/6) of patients died from tumor progression, both with GIST diagnosis (Table 2) .
Discussion
We described an infant with CHS-related hemangioendothelioma successfully treated with vincristine. CHS is an uncommon and severe form of hypothyroidism that occurs due to increased activity of D3, resulting in high rates of inactivation of thyroid hormones. The laboratory hallmark of this condition is high TSH levels and low serum T 4 and T 3 levels, accompanied by high rT 3 serum levels. High doses of LT 4 and/or LT 3 are required to normalize serum thyroid hormone levels. Usually, after successful tumor treatment, a euthyroid state is achieved. The CHS case reported here presented all characteristic features of the condition.
A systematic review showed that 97% of CHS in children were due to vascular tumors, with only 1 case of a solid tumor -a congenital fibrosarcoma. Conversely, in adults, with only 6 cases reported, vascular tumors, fibrous tumors, and GIST each accounted for 33% of the occurrences. Direct tumor therapy is an essential component of CHS treatment. The modalities employed are multiple, and the treatment strategies used vary according to tumor histology, patient characteristics, center experience, and available resources [5] . In children, the conservative treatment was preferred due to the favorable response of vascular tumors to medical treatment. Tumor resection was needed in only 2 cases: one case of fibrosarcoma and 1 hypervascularized vascular tumor where malignancy was suspected. While in adults the surgical treatment was predominant since most tumors were of nonvascular histology, in children the optimal tumor-directed treatment needs to be individualized according to specific patient and tumor characteristics, along with center experience and available resources.
The diagnosis of CHS requires a high suspicion index in patients with positive neonatal screening for hypothyroidism [6] . Of note, in our review, neonatal screening identified 32% (7/22) of CHS cases in children as congenital hypothyroidism. Some characteristics can help to differentiate CHS from other forms of congenital hypothyroidism, namely, normal thyroid morphology and iodine incorporation, high levels of rT 3 and the requirement of high doses of LT 4 /LT 3 to restore serum TSH normal levels [6] . Notwithstanding, since hemangiomas are the most common vascular tumors in children, occurring in approximately 5-10% of 1-year-old children [7] , it is reasonable to speculate that the actual prevalence of CHS may be underestimated. In this regard, further studies are warrant- T r a n s p l a n t a t i o n ed to explore the association of hemangiomas and clinical/ subclinical thyroid dysfunction. From now on, it would be adequate to include serum TSH screening in the evaluation of patients with hemangiomas, particularly the larger ones. In summary, we provide a summarized description of the 42 cases of CHS reported to date, highlighting the importance of an aggressive high-dose replacement of thyroid hormones along with early effective tumor-directed treatment approaches. Further efforts to support the development of treatment protocols to optimize thyroid hormone replacement and direct tumor treatments are warranted and should be the focus of future studies. Due to the high prevalence of vascular tumors in neonates, one should be aware of the necessity to include CHS in the differential diagnosis of congenital hypothyroidism.
